BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11

• Press Releases

  Kainova Therapeutics Announces Positive Phase I Results for DT-9081, an Oral EP4 Receptor Antagonist, in Advanced Solid Tumors

  March 10, 2026

   · 

  5 min read
• Press Releases

  EnteroBiotix Announces Completion of Enrolment in Phase 2a Trial Evaluating EBX-102-02 Prior to Allogeneic Stem Cell Transplantation

  March 10, 2026

   · 

  4 min read
• Press Releases

  For the First Time, Ferring Reports Revenue of Over €2.5 Billion in 2025

  March 10, 2026

   · 

  3 min read
• Press Releases

  BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day

  March 10, 2026

   · 

  7 min read
• Press Releases

  BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

  March 10, 2026

   · 

  35 min read
• Press Releases

  BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030

  March 10, 2026

   · 

  8 min read
• Press Releases

  Ascletis Announces Positive Topline Results from U.S. Phase II, 24-Week Study for Its Ultra-Long-Acting Subcutaneous Depot Formulations of Small Molecule GLP-1R Agonist ASC30 for Obesity

  March 10, 2026

   · 

  6 min read
• Press Releases

  Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium

  March 10, 2026

   · 

  9 min read
• Press Releases

  Everest Medicines to Announce 2025 Full-Year Financial Results on March 26, 2026

  March 10, 2026

   · 

  3 min read
• Press Releases

  NMD Pharma late breaking oral presentation at the MDA Conference with top-line safety and efficacy data from SYNAPSE-CMT, an exploratory Phase 2a clinical study of ignaseclant in Charcot-Marie-Tooth disease Types 1 & 2

  March 10, 2026

   · 

  8 min read